Emergent BioSolutions Inc. (EBS) Analysts See $0.30 EPS; Tocqueville Asset Management LP Cut Its Ametek (AME) Position

April 17, 2018 - By Stephen Andrade

AMETEK, Inc. (NYSE:AME) Logo

Analysts expect Emergent BioSolutions Inc. (NYSE:EBS) to report $0.30 EPS on May, 3.They anticipate $0.01 EPS change or 3.45% from last quarter’s $0.29 EPS. EBS’s profit would be $14.94 million giving it 45.31 P/E if the $0.30 EPS is correct. After having $0.74 EPS previously, Emergent BioSolutions Inc.’s analysts see -59.46% EPS growth. The stock increased 1.19% or $0.64 during the last trading session, reaching $54.37. About 26,147 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 82.65% since April 17, 2017 and is uptrending. It has outperformed by 71.10% the S&P500.

Tocqueville Asset Management Lp decreased Ametek Inc. (AME) stake by 35.8% reported in 2017Q4 SEC filing. Tocqueville Asset Management Lp sold 4,350 shares as Ametek Inc. (AME)’s stock rose 3.40%. The Tocqueville Asset Management Lp holds 7,800 shares with $565,000 value, down from 12,150 last quarter. Ametek Inc. now has $17.58 billion valuation. The stock increased 0.41% or $0.31 during the last trading session, reaching $75.91. About 138,028 shares traded. AMETEK, Inc. (NYSE:AME) has risen 40.32% since April 17, 2017 and is uptrending. It has outperformed by 28.77% the S&P500.

Analysts await AMETEK, Inc. (NYSE:AME) to report earnings on May, 2 before the open. They expect $0.72 EPS, up 20.00% or $0.12 from last year’s $0.6 per share. AME’s profit will be $166.71 million for 26.36 P/E if the $0.72 EPS becomes a reality. After $0.70 actual EPS reported by AMETEK, Inc. for the previous quarter, Wall Street now forecasts 2.86% EPS growth.

Investors sentiment increased to 1.29 in Q4 2017. Its up 0.09, from 1.2 in 2017Q3. It increased, as 30 investors sold AME shares while 150 reduced holdings. 69 funds opened positions while 163 raised stakes. 192.20 million shares or 0.03% more from 192.13 million shares in 2017Q3 were reported. Glob X Lc reported 5,988 shares. Asset Management, a Michigan-based fund reported 19,333 shares. Sei Invests Communication holds 205,908 shares. 361,085 were reported by Thrivent Financial For Lutherans. Oak Ridge Invs Ltd Liability holds 0.67% of its portfolio in AMETEK, Inc. (NYSE:AME) for 194,995 shares. California-based West Oak Limited Liability Corp has invested 0.22% in AMETEK, Inc. (NYSE:AME). New York State Common Retirement Fund reported 815,455 shares. Legal General Gru Plc owns 1.15 million shares. Mountain Pacific Advisers Id holds 4.11% or 539,191 shares in its portfolio. Contravisory Invest Inc holds 0.14% of its portfolio in AMETEK, Inc. (NYSE:AME) for 5,201 shares. Adage Capital Ltd Liability Company owns 0.13% invested in AMETEK, Inc. (NYSE:AME) for 775,306 shares. The Alabama-based Leavell Mngmt has invested 0.05% in AMETEK, Inc. (NYSE:AME). Capital Counsel reported 0.1% of its portfolio in AMETEK, Inc. (NYSE:AME). Ahl Prns Llp owns 76,106 shares for 0.09% of their portfolio. Advantus Incorporated reported 23,771 shares.

Tocqueville Asset Management Lp increased Detour Gold Corporation (DRGDF) stake by 5.47M shares to 5.85M valued at $68.79 million in 2017Q4. It also upped Mckesson Corporation (NYSE:MCK) stake by 3,270 shares and now owns 41,099 shares. Bhp Billiton Limited (NYSE:BHP) was raised too.

Among 14 analysts covering AMETEK (NYSE:AME), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AMETEK had 63 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 8 by Stifel Nicolaus. Oppenheimer maintained it with “Outperform” rating and $54 target in Friday, August 5 report. The firm earned “Buy” rating on Wednesday, August 5 by Oppenheimer. The stock of AMETEK, Inc. (NYSE:AME) has “Overweight” rating given on Friday, February 2 by KeyBanc Capital Markets. The stock has “Buy” rating by RBC Capital Markets on Wednesday, October 11. BMO Capital Markets initiated the stock with “Outperform” rating in Tuesday, April 5 report. The firm earned “Buy” rating on Wednesday, September 20 by Jefferies. Atlantic Securities upgraded the stock to “Overweight” rating in Wednesday, February 15 report. Robert W. Baird maintained AMETEK, Inc. (NYSE:AME) rating on Friday, November 3. Robert W. Baird has “Outperform” rating and $77 target. The company was maintained on Tuesday, April 3 by Stifel Nicolaus.

Since December 11, 2017, it had 0 insider purchases, and 13 insider sales for $9.09 million activity. Shares for $2.04 million were sold by Hardin John Wesley. The insider EGINTON WILLIAM D sold 16,368 shares worth $1.26 million. $1.13 million worth of AMETEK, Inc. (NYSE:AME) was sold by Oscher Ronald J on Thursday, February 15. The insider Kohlhagen Steven W sold 5,000 shares worth $393,199. VARET ELIZEBETH R sold $470,375 worth of stock or 6,295 shares. Conti Anthony James sold $316,476 worth of stock. Shares for $309,672 were sold by WILLIAMS DENNIS K on Thursday, February 22.

Investors sentiment increased to 2.02 in Q4 2017. Its up 0.33, from 1.69 in 2017Q3. It is positive, as 11 investors sold Emergent BioSolutions Inc. shares while 53 reduced holdings. 45 funds opened positions while 84 raised stakes. 36.89 million shares or 8.80% more from 33.90 million shares in 2017Q3 were reported. Acadian Asset Mgmt Limited Company holds 0.29% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 1.45 million shares. Pnc Service Grp has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 1,365 shares. Globeflex Cap L P owns 6,924 shares. Boston Advsrs invested in 132,332 shares. The Pennsylvania-based Smithfield has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Putnam Invests Limited Co accumulated 41,254 shares or 0% of the stock. Louisiana State Employees Retirement System reported 15,100 shares. State Street owns 1.50 million shares. Stifel Financial Corporation stated it has 14,809 shares or 0% of all its holdings. Rhumbline Advisers holds 82,228 shares or 0.01% of its portfolio. Bancorporation Of Mellon Corp holds 0.01% or 573,450 shares in its portfolio. Tiaa Cref Inv Mgmt Limited Liability Corporation accumulated 168,470 shares or 0.01% of the stock. State Teachers Retirement holds 0% or 35,652 shares in its portfolio. Geode Capital Mngmt Ltd has invested 0.01% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Qs Invsts Ltd Liability holds 107,140 shares.

Among 5 analysts covering Emergent Biosolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent Biosolutions had 9 analyst reports since August 10, 2015 according to SRatingsIntel. Singular Research initiated the stock with “Buy” rating in Monday, March 28 report. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Buy” rating by Singular Research on Tuesday, June 28. The firm has “Buy” rating given on Tuesday, February 27 by Singular Research. Cowen & Co maintained it with “Hold” rating and $3300 target in Friday, July 14 report. Chardan Capital Markets initiated it with “Buy” rating and $47 target in Friday, April 15 report. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19. The company was upgraded on Monday, August 10 by Zacks.

Since December 12, 2017, it had 0 insider buys, and 6 insider sales for $3.83 million activity. Another trade for 20,000 shares valued at $919,800 was sold by Abdun-Nabi Daniel. Havey Adam had sold 1,898 shares worth $93,951 on Tuesday, February 27. $391,787 worth of Emergent BioSolutions Inc. (NYSE:EBS) was sold by Hauer Jerome M. Richard Ronald sold $1.07M worth of stock or 23,681 shares.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.71 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 31.87 P/E ratio. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: